ArticleBMC infectious diseases2015
Epidemiological, clinical, outcome and antibiotic susceptibility differences between PVL positive and PVL negative Staphylococcus aureus infections in Western Australia: a case control study.
Article in BMC infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 39 citations in OpenAlex.
- Genomic Characterization and Virulence Determinants ofAntibiotics (Basel, Switzerland) · 2026Article
- Early Diagnosis and Successful Treatment of Influenza Coinfection With Community-Onset Methicillin-ResistantCase reports in infectious diseases · 2026Article
- Phenotypic and Genotypic Characterization ofPathogens (Basel, Switzerland) · 2025Article
- 20 years later: unravelling the genomic success of New Zealand's home-grown AK3 community-associated methicillin-resistantMicrobial genomics · 2025Article
- Article
- Molecular detection of phenol-soluble modulin-mec (PSM-mec) in Staphylococcus aureus clinical isolates from Federal Medical Center Birnin Kebbi, North-West, Nigeria.GMS hygiene and infection control · 2025Article
- Article
- Does Adjunctive Clindamycin Have a Role in Staphylococcus aureus Bacteremia? A Protocol for the Adjunctive Treatment Domain of the Staphylococcus aureus Network Adaptive Platform (SNAP) Randomized Controlled Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Article
- Prevalence of Panton-Valentine leucocidin (F1000Research · 2023Article
- Clindamycin adjunctive therapy for severeJAC-antimicrobial resistance · 2022Article
- Successful treatment of pleural empyema and necrotizing pneumonia caused by methicillin-resistantFrontiers in pediatrics · 2022Article
- Investigation of Virulence Genes ofThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2021Article
- Marked increase in community-associated methicillin-resistantEpidemiology and infection · 2020Article
- Evolution of a 72-Kilobase Cointegrant, Conjugative Multiresistance Plasmid in Community-Associated Methicillin-Resistant Staphylococcus aureus Isolates from the Early 1990s.Antimicrobial agents and chemotherapy · 2019Article
- Severe infections of Panton-Valentine leukocidin positive Staphylococcus aureus in children.Medicine · 2019Article
- Article
- Observational
- Panton-Valentine Leucocidin (PVL) as a Potential Indicator for Prevalence, Duration, and Severity ofFrontiers in microbiology · 2017Article
- The Epidemiology of Staphylococcus aureus and Panton-Valentine Leucocidin (pvl) in Central Australia, 2006-2010.BMC infectious diseases · 2016Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPanton Valentine Leukocidin (PVL) has been associated with invasive Staphylococcus aureus soft tissue and pneumonic infections.
methodsFrom September 2007 to January 2009 at Royal Perth Hospital we tested for the PVL gene in S. aureus isolates from an invasive site, a suspected PVL-related soft tissue infection and all MRSA isolates. We could access medical records for 141 PVL positive (PVL + ve) infections and compared these to a control group comprised of 148 PVL negative (PVL-ve) infections.
resultsIn the PVL + ve group 62 isolates were MRSA (48 were ST93-MRSA-IV) and 79 isolates were methicillin-sensitive S. aureus, and in the PVL-ve group 56 were MRSA (50 were WA-MRSA strains) and 92 were methicillin-sensitive S. aureus. We found the presence of PVL to be significantly associated with younger age, aboriginality, intravenous drug use, community acquisition, shorter length of hospital stay and lower mortality at 1 year. Overall PVL + ve infections more often required surgical intervention (73.0% versus 44.6%, p < 0.001) and were less often polymicrobial (8.5% versus 41.2%, p < 0.001). PVL + ve isolates were more often susceptible to clindamycin (87.9% versus 73.0%, p = 0.002).
conclusionsThis study demonstrates that PVL + ve infections are associated with a distinct clinical picture, predominantly pyogenic skin and soft tissue infections often requiring surgery, disproportionately affecting patients who are younger, indigenous or with fewer health-care risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.